ImmunityBio Director Simon Barry Executes Rule 10b5-1 Sale of $165,305 in Shares
ImmunityBio, Inc. (NASDAQ: IBRX) director Simon Barry J. completed a sale of 23,033 common shares on June 4, 2026, generating approximately $165,305 in proceeds. The transaction was structured under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. This sale occurs against a backdrop of substantial year-to-date stock appreciation, t…